A Combinatorial Strategy for Targeting BRAFV600E-Mutant Cancers with BRAFV600E Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)

被引:14
|
作者
Ghosh, Chandrayee [1 ]
Kumar, Suresh [2 ]
Kushchayeva, Yevgeniya [3 ]
Gaskins, Kelli [4 ]
Boufraqech, Myriem [4 ]
Wei, Darmood [4 ]
Gara, Sudheer Kumar [4 ]
Zhang, Lisa [5 ]
Zhang, Ya-qin [6 ]
Shen, Min [6 ]
Mukherjee, Sanjit [7 ]
Kebebew, Electron [1 ]
机构
[1] Stanford Univ, Dept Surg, Stanford, CA 94305 USA
[2] NIA, Lab Genet & Genom, Bethesda, MD 20892 USA
[3] Natl Inst Digest & Kidney Dis, NIH, Bethesda, MD USA
[4] NCI, NIH, Bethesda, MD 20892 USA
[5] Natl Inst Child Hlth & Dev, NIH, Bethesda, MD USA
[6] NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA
[7] NCI, Genet Branch, Bethesda, MD 20892 USA
关键词
ANAPLASTIC THYROID-CANCER; ACQUIRED-RESISTANCE; BRAF INHIBITION; MEK INHIBITION; TUMOR-GROWTH; QUANTIFICATION; CARFILZOMIB; VEMURAFENIB; MECHANISMS; PATHWAYS;
D O I
10.1158/1078-0432.CCR-19-1606
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Most aggressive thyroid cancers are commonly associated with a BRAF(V600E) mutation. Preclinical and clinical data in BRAF(V600E) cancers suggest that combined BRAF and MEK inhibitor treatment results in a response, but resistance is common. One mechanism of acquired resistance is through persistent activation of tyrosine kinase (TK) signaling by alternate pathways. We hypothesized that combination therapy with BRAF and multitargeting TK inhibitors (MTKI) might be more effective in BRAF(V600E) thyroid cancer than in single-agent or BRAF and MEK inhibitors. Experimental Design: The combined drug activity was analyzed to predict any synergistic effect using high-throughput screening (HTS) of active drugs. We performed follow-up in vitro and in vivo studies to validate and determine the mechanism of action of synergistic drugs. Results: The MTKI ponatinib and the BRAF inhibitor PLX4720 showed synergistic activity by HTS. This combination significantly inhibited proliferation, colony formation, invasion, and migration in BRAF(V600E) thyroid cancer cell lines and downregulated pERK/MEK and c-JUN signaling pathways, and increased apoptosis. PLX4720-resistant BRAF(V600E) cells became sensitized to the combination treatment, with decreased proliferation at lower PLX4720 concentrations. In an orthotopic thyroid cancer mouse model, combination therapy significantly reduced tumor growth (P < 0.05), decreased the number of metastases (P < 0.05), and increased survival (P < 0.05) compared with monotherapy and vehicle control. Conclusions: Combination treatment with ponatinib and PLX4720 exhibited significant synergistic anticancer activity in preclinical models of BRAF(V600E) thyroid cancer, in addition to overcoming PLX4720 resistance. Our results suggest this combination should be tested in clinical trials.
引用
收藏
页码:2022 / 2036
页数:15
相关论文
共 50 条
  • [1] COMBINED BRAFV600E AND MEK INHIBITION FOR BRAFV600E-MUTANT ASTROCYTOMAS
    Zhang, Jie
    Hariono, Sujatmi
    Yao, Tsun-Wen
    Sidhu, Angadpreet
    Hashizume, Rintaro
    James, C. David
    Weiss, William A.
    Nicolaides, Theodore P.
    [J]. NEURO-ONCOLOGY, 2013, 15 : 60 - 61
  • [2] Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
    Zhang, Jie
    Yao, Tsun-Wen
    Hashizume, Rintaro
    Hariono, Sujatmi
    Barkovich, Krister J.
    Fan, Qi-Wen
    Prados, Michael
    James, C. David
    Weiss, William A.
    Nicolaides, Theodore
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2017, 131 (03) : 495 - 505
  • [3] Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas
    Jie Zhang
    Tsun-Wen Yao
    Rintaro Hashizume
    Sujatmi Hariono
    Krister J. Barkovich
    Qi-Wen Fan
    Michael Prados
    C. David James
    William A. Weiss
    Theodore Nicolaides
    [J]. Journal of Neuro-Oncology, 2017, 131 : 495 - 505
  • [4] Combination BRAFV600E Inhibition with the Multitargeting Tyrosine Kinase Inhibitor Axitinib Shows Additive Anticancer Activity in BRAFV600E-Mutant Anaplastic Thyroid Cancer
    Gunda, Viswanath
    Ghosh, Chandrayee
    Hu, Jiangnan
    Zhang, Lisa
    Zhang, Ya qin
    Shen, Min
    Kebebew, Electron
    [J]. THYROID, 2023, 33 (10) : 1201 - 1214
  • [5] Cyp24a1 Attenuation Limits Progression of BrafV600E-Induced Papillary Thyroid Cancer Cells and Sensitizes Them to BRAFV600E Inhibitor PLX4720
    Zou, Minjing
    Baitei, Essa Y.
    BinEssa, Huda A.
    Al-Mohanna, Futwan A.
    Parhar, Ranjit S.
    St-Arnaud, Rene
    Kimura, Shioko
    Pritchard, Catrin
    Alzahrani, Ali S.
    Assiri, Abdullah M.
    Meyer, Brian F.
    Shi, Yufei
    [J]. CANCER RESEARCH, 2017, 77 (08) : 2161 - 2172
  • [6] Computational investigation on inhibition mechanism of BRAFV600E by Vemurafenib (PLX4032) and its analogue PLX4720
    XiaoYun Wu
    Yu Fu
    YuanYuan Wang
    ShanHe Wan
    JiaJie Zhang
    [J]. Medicinal Chemistry Research, 2017, 26 : 390 - 396
  • [7] Selective BRAFV600E Inhibitor PLX4720, Requires TRAIL Assistance to Overcome Oncogenic PIK3CA Resistance
    Oikonomou, Eftychia
    Koc, Michal
    Sourkova, Vladimira
    Andera, Ladislav
    Pintzas, Alexander
    [J]. PLOS ONE, 2011, 6 (06):
  • [8] Computational investigation on inhibition mechanism of BRAFV600E by Vemurafenib (PLX4032) and its analogue PLX4720
    Wu, XiaoYun
    Fu, Yu
    Wang, YuanYuan
    Wan, ShanHe
    Zhang, JiaJie
    [J]. MEDICINAL CHEMISTRY RESEARCH, 2017, 26 (02) : 390 - 396
  • [9] BRAFv600E INHIBITOR(VEMURAFENIB) IN PEDIATRIC PATIENTS AFFECTED BY BRAFv600E MUTATED GLIOMAS
    del Bufalo, Francesca
    Cacchione, Antonella
    Carai, Andrea
    Antonelli, Manila
    Giangaspero, Felice
    Ferretti, Elisabetta
    Catanzaro, Giuseppina
    Miele, Evelina
    Badiali, Manuela
    Pettorini, Benedetta
    Mastronuzzi, Angela
    [J]. NEURO-ONCOLOGY, 2016, 18 : 24 - 24
  • [10] SURVIVAL ADVANTAGE WITH EVEROLIMUS (RAD001) COMBINED WITH A SELECTIVE BRAFV600E INHIBITOR IN A XENOGRAFT MODEL OF BRAFV600E-MUTANT PEDIATRIC GLIOMA
    Dasgupta, Tina
    Olow, Aleksandra
    Yang, Xiaodong
    Hashizume, Rintaro
    Mueller, Sabine
    Nicolaides, Theodore
    Kolkowitz, Ilan
    Weiss, William
    Prados, Michael
    Gupta, Nalin
    James, C. David
    Haas-Kogan, Daphne
    [J]. NEURO-ONCOLOGY, 2013, 15 : 43 - 43